Cannara Biotech Stock Price To Earning
| LOVFF Stock | USD 0.51 0.03 5.56% |
Cannara Biotech fundamentals help investors to digest information that contributes to Cannara Biotech's financial success or failures. It also enables traders to predict the movement of Cannara OTC Stock. The fundamental analysis module provides a way to measure Cannara Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cannara Biotech otc stock.
Cannara |
Cannara Biotech OTC Stock Price To Earning Analysis
Cannara Biotech's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Cannara Biotech Price To Earning | 85.00 X |
Most of Cannara Biotech's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cannara Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Based on the latest financial disclosure, Cannara Biotech has a Price To Earning of 85 times. This is 228.95% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The price to earning for all United States stocks is 195.96% lower than that of the firm.
Cannara Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cannara Biotech's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Cannara Biotech could also be used in its relative valuation, which is a method of valuing Cannara Biotech by comparing valuation metrics of similar companies.Cannara Biotech is currently under evaluation in price to earning category among its peers.
Cannara Fundamentals
| Return On Equity | 0.0434 | |||
| Return On Asset | 0.0327 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.15 % | |||
| Current Valuation | 94.03 M | |||
| Shares Outstanding | 877.48 M | |||
| Shares Owned By Insiders | 47.54 % | |||
| Price To Earning | 85.00 X | |||
| Price To Book | 1.37 X | |||
| Price To Sales | 1.81 X | |||
| Revenue | 35.84 M | |||
| Gross Profit | 17.33 M | |||
| EBITDA | 8.14 M | |||
| Net Income | 2.31 M | |||
| Cash And Equivalents | 3.88 M | |||
| Total Debt | 46.19 M | |||
| Debt To Equity | 0.49 % | |||
| Current Ratio | 2.13 X | |||
| Book Value Per Share | 0.08 X | |||
| Cash Flow From Operations | (6.08 M) | |||
| Earnings Per Share | 0.15 X | |||
| Beta | 1.52 | |||
| Market Capitalization | 63.27 M | |||
| Total Asset | 125.62 M | |||
| Z Score | 0.6 | |||
| Net Asset | 125.62 M |
About Cannara Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cannara Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cannara Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cannara Biotech based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Cannara OTC Stock
Cannara Biotech financial ratios help investors to determine whether Cannara OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cannara with respect to the benefits of owning Cannara Biotech security.